349 related articles for article (PubMed ID: 22736069)
81. Romosozumab in patients who experienced an on-study fracture: post hoc analyses of the FRAME and ARCH phase 3 trials.
Lane J; Langdahl B; Stone M; Kurth A; Oates M; Timoshanko J; Wang Z; Libanati C; Cosman F
Osteoporos Int; 2024 Jul; 35(7):1195-1204. PubMed ID: 38573517
[TBL] [Abstract][Full Text] [Related]
82. Intervention thresholds for denosumab in the UK using a FRAX®-based cost-effectiveness analysis.
Ström O; Jönsson B; Kanis JA
Osteoporos Int; 2013 Apr; 24(4):1491-502. PubMed ID: 23224141
[TBL] [Abstract][Full Text] [Related]
83. The effectiveness of ibandronate in reducing the risk of nonvertebral fractures in women with osteoporosis: systematic review and meta-analysis of observational studies.
Alves C; Mendes D; Penedones A; Oliveira T; Donato A; Batel-Marques F
Int J Clin Pharm; 2024 Apr; 46(2):357-367. PubMed ID: 38112890
[TBL] [Abstract][Full Text] [Related]
84. Significance of a decline in bone mineral density while receiving oral bisphosphonate treatment.
Sebba AI
Clin Ther; 2008 Mar; 30(3):443-52. PubMed ID: 18405784
[TBL] [Abstract][Full Text] [Related]
85. Clinical pharmacology of potent new bisphosphonates for postmenopausal osteoporosis.
Chapurlat RD
Treat Endocrinol; 2005; 4(2):115-25. PubMed ID: 15783248
[TBL] [Abstract][Full Text] [Related]
86. Bisphosphonate drug holidays in postmenopausal osteoporosis: effect on clinical fracture risk.
Mignot MA; Taisne N; Legroux I; Cortet B; Paccou J
Osteoporos Int; 2017 Dec; 28(12):3431-3438. PubMed ID: 28875236
[TBL] [Abstract][Full Text] [Related]
87. [Bisphosphonate treatment prevents hip fractures in 70-79 year old women with osteoporotic vertebral fractures].
Netelenbos JC
Ned Tijdschr Geneeskd; 2001 Jul; 145(28):1336-8. PubMed ID: 11484428
[TBL] [Abstract][Full Text] [Related]
88. Prevention and treatment of glucocorticoid-induced osteoporosis in 2005.
Orcel P
Joint Bone Spine; 2005 Dec; 72(6):461-5. PubMed ID: 16326129
[TBL] [Abstract][Full Text] [Related]
89. Risk of atypical femoral fracture during and after bisphosphonate use.
Schilcher J; Koeppen V; Aspenberg P; Michaëlsson K
Acta Orthop; 2015 Feb; 86(1):100-7. PubMed ID: 25582459
[TBL] [Abstract][Full Text] [Related]
90. The effect of teriparatide compared with risedronate on reduction of back pain in postmenopausal women with osteoporotic vertebral fractures.
Hadji P; Zanchetta JR; Russo L; Recknor CP; Saag KG; McKiernan FE; Silverman SL; Alam J; Burge RT; Krege JH; Lakshmanan MC; Masica DN; Mitlak BH; Stock JL
Osteoporos Int; 2012 Aug; 23(8):2141-50. PubMed ID: 22159672
[TBL] [Abstract][Full Text] [Related]
91. Efficacy of Pharmacological Therapies for the Prevention of Fractures in Postmenopausal Women: A Network Meta-Analysis.
Barrionuevo P; Kapoor E; Asi N; Alahdab F; Mohammed K; Benkhadra K; Almasri J; Farah W; Sarigianni M; Muthusamy K; Al Nofal A; Haydour Q; Wang Z; Murad MH
J Clin Endocrinol Metab; 2019 May; 104(5):1623-1630. PubMed ID: 30907957
[TBL] [Abstract][Full Text] [Related]
92. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases.
Siris ES; Harris ST; Rosen CJ; Barr CE; Arvesen JN; Abbott TA; Silverman S
Mayo Clin Proc; 2006 Aug; 81(8):1013-22. PubMed ID: 16901023
[TBL] [Abstract][Full Text] [Related]
93. Going on a drug holiday?
Bonnick SL
J Clin Densitom; 2011; 14(4):377-83. PubMed ID: 22051091
[No Abstract] [Full Text] [Related]
94. Long-term fracture rates seen with continued ibandronate treatment: pooled analysis of DIVA and MOBILE long-term extension studies.
Miller PD; Recker RR; Harris S; Silverman S; Felsenberg D; Reginster J; Day BM; Barr C; Masanauskaite D
Osteoporos Int; 2014 Jan; 25(1):349-57. PubMed ID: 24136103
[TBL] [Abstract][Full Text] [Related]
95. An approach to postmenopausal osteoporosis treatment: a case study review.
Kessenich C
J Am Acad Nurse Pract; 2003 Dec; 15(12):539-45. PubMed ID: 14983569
[TBL] [Abstract][Full Text] [Related]
96. Cost-effectiveness of romosozumab for the treatment of postmenopausal women at very high risk of fracture in Canada.
Goeree R; Burke N; Jobin M; Brown JP; Lawrence D; Stollenwerk B; Willems D; Johnson B
Arch Osteoporos; 2022 Apr; 17(1):71. PubMed ID: 35471711
[TBL] [Abstract][Full Text] [Related]
97. Bisphosphonates and osteoporotic fractures: a cross-design synthesis of results among compliant/persistent postmenopausal women in clinical practice versus randomized controlled trials.
Wilkes MM; Navickis RJ; Chan WW; Lewiecki EM
Osteoporos Int; 2010 Apr; 21(4):679-88. PubMed ID: 19572092
[TBL] [Abstract][Full Text] [Related]
98. Efficacy of teriparatide compared with risedronate on FRAX
Body JJ; Marin F; Kendler DL; Zerbini CAF; López-Romero P; Möricke R; Casado E; Fahrleitner-Pammer A; Stepan JJ; Lespessailles E; Minisola S; Geusens P
Osteoporos Int; 2020 Oct; 31(10):1935-1942. PubMed ID: 32474650
[TBL] [Abstract][Full Text] [Related]
99. Medical treatment of vertebral osteoporosis.
Lippuner K
Eur Spine J; 2003 Oct; 12 Suppl 2(Suppl 2):S132-41. PubMed ID: 13680313
[TBL] [Abstract][Full Text] [Related]
100. Duration of Bisphosphonate Drug Holidays and Associated Fracture Risk.
Curtis JR; Saag KG; Arora T; Wright NC; Yun H; Daigle S; Matthews R; Delzell E
Med Care; 2020 May; 58(5):419-426. PubMed ID: 31985584
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
